¹ Dx: assess severity based on hx/PE (viral URI prodrome, rhinorrhea, cough, tachypnea, wheezing, rales, grunting, nasal flaring, apnea) [B/S]. Assess resp rate, retractions, O2 sat, and risk factors for severe dz: age <12 wks, prematurity, cardiopulmonary dz, in utero smoke exposure, immunodeficiency, congenital anomalies [B/M]. X-ray, lab studies not routinely recommended [B/M]; exception: test for RSV in hospitalized infants on palivizumab to determine breakthrough infxn; CXR for unexpected worsening, ICU admission, suspected airway complication (eg, pneumothorax).

² Exclusions: Children w/ acidosis or fever.

³ Use of pulse oximetry may prolong hospitalization.

⁴ AAP no longer recommends trial of albuterol, as in 2006 guideline.

⁵ Suctioning of the nares may be beneficial, but not routine deep suctioning.

⁶ Do not administer antibiotics unless concomitant bacterial infxn present/strongly suspected [B/S]. Refer to AAP AOM guidelines if otitis media suspected.

⁷ Dx: assess severity based on hx/PE (viral URI prodrome, rhinorrhea, cough, tachypnea, wheezing, rales, grunting, nasal flaring, apnea) [B/S]. Assess resp rate, retractions, O2 sat, and risk factors for severe dz: age <12 wks, prematurity, cardiopulmonary dz, in utero smoke exposure, immunodeficiency, congenital anomalies [B/M]. X-ray, lab studies not routinely recommended [B/M]; exception: test for RSV in hospitalized infants on palivizumab to determine breakthrough infxn; CXR for unexpected worsening, ICU admission, suspected airway complication (eg, pneumothorax).

⁸ Exclusions: Children w/ acidosis or fever.

⁹ May choose not to use continuous pulse ox [C/W]; use of pulse ox may prolong hospitalization.

¹⁰ Suctioning of nares may be beneficial, but not routine deep suctioning.